Alicante

• MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended
  2023-503615-14-00 4 2022-09-29 Relapsed or Refractory Classical Hodgkin Lymphoma
• A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02) Ended
  2024-513993-23-00 9 2022-09-21 Patients with higher risk myelodysplastic syndrome (MDS) who have not
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis. Ended
  2024-512791-36-00 4 2022-08-24 Treatment of moderate-to-severe Atopic dermatitis
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
• Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patien … Ended
  2024-519527-14-00 5 2022-06-09 Allergic rhinoconjunctivitis
• ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion Ended
  2023-508454-26-00 6 2022-05-01 Acute Ischemic Stroke
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended
  2023-508828-35-01 5 2022-03-28 Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
• Predicting olaparib sensitivity in metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutation or RAD51-negat … Ended
  2024-511875-14-00 4 2022-03-24 Pre and post-menopausal women and men with unresectable locally advanc
• CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIM … Ended
  2024-513123-17-00 5 2022-01-12 Non-infection uveitis
• Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progress … Ended
  2024-518875-73-00 5 2021-12-10 Huntington Disease
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr … Ended
  2024-514611-98-00 5 2021-07-20 PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previousl
• A study designed to evaluate a modified Anti-Platelet Therapy (drugs that preventblood platelets from clotting) after implantation of a Fire … Ended
  2024-519854-35-00 6 2021-06-29 Acute Myocardial Infarction
• DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial Ended
  2024-515167-56-00 11 2021-06-22 HIV
• Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c … Ended
  2024-514803-33-00 4 2021-06-16 Non-small cell lung cancer (NSCLC)
• HOPE study Ended
  2024-516642-19-01 6 2021-06-16 Acute Ischemic Stroke
• A trial to assess the long-term safety of octreotide subcutaneous depot in patients with acromegaly Ended
  2024-510667-33-00 5 2021-06-03 Acromegaly
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended
  2023-504991-31-00 5 2021-05-06 Agitation in Patients With Dementia of the Alzheimer's Type
• A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended
  2023-509591-42-00 4 2021-05-04 HR-positive/HER2-negative breast cancer
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients … Ended
  2024-511295-33-00 4 2020-08-13 Study to evaluate the effect of metformin in the prevention of hypergl
• Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended
  2024-514090-21-00 5 2020-08-05 Aetiological treatment of moderate - severe intermittent or persistent
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)

Showing 265–288 of 301 trials